

JNJ · NYSE · WEEK ENDED 24 JUL 2026

Weekly Investor Report

Johnson & Johnson · Healthcare · Drug Manufacturers - General

LATEST CLOSE

263.4 USD

4.1% latest week

Weekly setup

Constructive, but selective

The weekly trend is active. Price is 12.2% above the Trend Line and sits at 94.5% of its 52-week range. The latest completed week returned 4.1%, after a 3.4% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers. Options positioning is bullish with 48/100 conviction, while the latest news-sentiment score is 54/100. Near-term considerations: price is close to its 52-week high; earnings are due in 76d.

Technical setup score 71/100. This score describes the weekly technical setup; the conclusion above also considers fundamentals, positioning, sentiment, and event risk.

LATEST CLOSE

263.4 USD

24 Jul 2026

1W RETURN

4.1%

latest completed week

4W RETURN

3.4%

short-term follow-through

12W RETURN

16.6%

quarterly tape

TREND BREADTH

100.0%

52 of 52 weeks active

VOLUME RATIO

1.0x

vs 13-week average

What is working

- The trend backdrop is active with a 69-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.

What could go wrong

- 4 reversal markers appear in the recent smart-money tape.
- Recent volatility is running well above the one-year baseline.

What to watch next

- Price is close to its 52-week high; watch for continuation or exhaustion.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.

This week's evidence at a glance

PRICE FOLLOW-THROUGH

4.1%

Latest completed week; four-week move 3.4%.

INDICATOR STACK

100/95

Trend and activity pressure are weighted against the latest 12-week confirmation window.

TREND BACKDROP

Active

The trend backdrop defines the current weekly regime.

PATIENT CAPITAL

Quiet

Activity-pressure buy-signal status for institutional accumulation timing.

OPTIONS PRESSURE

Bullish

48/100 conviction; expected move 2.2%.

NEWS SENTIMENT

54/100

38 relevant articles in the latest sentiment read.

EVENT RISK

76d


Next report is scheduled for 13 Oct 2026; event risk rises as the date approaches.

01 · PRICE ACTION

Where price is—and whether the trend supports it


The weekly trend is active. Price is 12.2% above the Trend Line and sits at 94.5% of its 52-week range. The latest completed week returned 4.1%, after a 3.4% four-week move.

52-week price path



Blue: weekly close · Green: Trend Line · Orange: Sharemaestro Fair Value

Position in the 52-week range



RANGE LOCATION

94.5%

Shows where the latest close sits between the 52-week low and high.

TREND DISTANCE

12.2%

Price premium or discount versus the weekly Trend Line.

FAIR-VALUE GAP

55.0%

Premium demand or model discount versus Sharemaestro Fair Value.

HIGH-WATER GAP

-2.2%

Distance from the latest 52-week high.


02 · VOLUME AND DEMAND

Is real participation confirming the move?

Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows weekly volume. Green marks an up week; orange marks a down week.



PARTICIPATION 1.0x Latest volume versus the 13-week average.	BASELINE 39.1M 13-week average volume.	ONE-YEAR BASE 40.7M 52-week average volume.	LATEST WEEKLY VOLUME 39.4M Most recent completed week.
---	---	--	---

Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath price. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.64 · 12-week average 0.59

12-week confirmation


Signal	Read	Meaning
Trend active	12/12	Active trend-backdrop weeks in the latest 12-week window.
Positive pressure	4/12	Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership	11/12	Weeks with positive relative leadership in the latest 12-week window.
Activity pressure	0.64	Current proprietary activity-pressure read.
Buy signals	0	Accumulation signal count in the latest 12 weeks.
Reversal markers	4	4 reversal markers

No recent accumulation markers. 4 reversal markers.

03 · MOMENTUM AND LEADERSHIP

Is performance persistent—and is the stock leading?

Performance is 3.4% over four weeks, 16.6% over 12 weeks, and 60.4% over one year. The current trend has remained active for 69 consecutive weeks.



Technical setup scorecard

Trend		100
Momentum		73
Activity Pressure		95
Relative Leadership		93
Next-Week Expectancy		50
Volume		42
Smart Money		39
Risk Control		78

04 · FUNDAMENTALS AND VALUATION

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers.

FACTOR WEEK 26 Jul 2026 Latest published factor snapshot.	STATEMENTS THROUGH 31 Dec 2025 Financial reporting period used.	FIELD COVERAGE 97% Available factor fields.	MODEL CONFIDENCE 97% Snapshot confidence.
--	--	--	--

Relative factor standing Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.		
Overall factor strength		51/100
Value		9/100
Quality		91/100
Momentum		89/100
Growth		31/100

Valuation How much investors are paying for earnings, sales, and cash flow.	Business quality Margins and the return generated on invested capital.
P/E Price divided by trailing earnings. 30.2x	GROSS MARGIN Gross profit retained from each unit of revenue. 70.5%
PRICE / SALES Market value relative to trailing revenue. 6.5x	OPERATING MARGIN Operating profit retained from revenue. 26.7%
EV / EBITDA Enterprise value relative to operating cash earnings. 20.8x	FREE-CASH-FLOW MARGIN Free cash flow generated from revenue. 29.3%
FREE-CASH-FLOW YIELD Free cash flow as a share of enterprise value. 4.3%	RETURN ON INVESTED CAPITAL Operating return generated on invested capital. 19.2%

04 · FUNDAMENTALS AND VALUATION · CONTINUED

Growth, shareholder returns, and balance-sheet strength

The second half of the fundamental read separates recent business growth from cash returned to shareholders and financial leverage.

Growth and financial strength	Shareholder return and balance sheet
Recent business growth and accounting strength.	Cash returned to owners and financial leverage.
REVENUE GROWTH8.1% Latest one-year revenue growth.	DIVIDEND YIELD2.0% Cash dividends relative to market value.
EPS GROWTH-7.2% Latest one-year earnings-per-share growth.	BUYBACK YIELD1.3% Net share repurchases relative to market value.
FREE-CASH-FLOW GROWTH-3.2% Latest one-year free-cash-flow growth.	SHAREHOLDER YIELD3.3% Dividend yield plus net buyback yield.
PIOTROSKI F-SCORE5/9 Nine-point accounting-strength checklist.	NET DEBT / EBITDA0.9x Balance-sheet debt relative to operating cash earnings.

How to read this

Quality and valuation are separate questions. A strong company can still carry a demanding valuation, so profitability, growth, balance-sheet strength, and the price paid for those characteristics should be assessed independently.

The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is expensive relative to peers.

05 · OWNERSHIP, OPTIONS, AND SENTIMENT

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioning

Bullish

JNJ shows bullish options pressure with a 48/100 conviction score, put-call volume ratio of 0.25, expected move of 2.2%, and Sharemaestro trend signal active.

CONVICTION

48/100

Options signal conviction.

EXPECTED MOVE

2.2%

Nearest-chain pricing.

PUT/CALL VOLUME

0.25

Contract volume balance.

Pressure

63

Speculation

43

Volatility

29

Trend agreement

34

Insider activity

13 / 7

13 acquisitions and 7 disposals in the latest 180-day insider tape. Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.

News sentiment

54/100

Weighted news tone is neutral across 38 relevant articles.

11 positive · 25 neutral · 2 negative

Patient Capital

Quiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows. No recent buy signal

06 · CATALYSTS AND RISK


What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly gains and losses frame the risk around the current setup.

NEXT EARNINGS 76d Next report is scheduled for 13 Oct 2026; event risk rises as the date approaches.	OPTIONS EXPECTED MOVE 2.2% Nearest-chain priced movement where available.	52-WEEK DRAWDOWN -2.2% Distance below the 52-week high.	13-WEEK VOLATILITY 4.2% Standard deviation of weekly returns.
--	---	---	---

Weekly gains and losses

Each bar is one completed week. Gains rise above zero; losses fall below it. Taller bars mean a larger move.



</

07 · SECTOR AND PEER CONTEXT

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

Sector · US Healthcare

4-WEEK RANK 36 / 100 Standing within the tracked group.	GROUP AVERAGE 1.3% Average four-week return.	TREND BREADTH 51.0% Share of peers with an active trend.
--	---	---

Peer	Exchange	1W return	4W return	Trend
ABVX	NASDAQ	-8.0%	28.9%	Active
THC	NYSE	19.6%	23.4%	Inactive
BBIO	NASDAQ	3.2%	19.6%	Active
ONC	NASDAQ	4.4%	16.4%	Inactive
MEDP	NASDAQ	11.8%	14.1%	Inactive

Industry · US Drug Manufacturers - General

4-WEEK RANK 4 / 20 Standing within the tracked group.	GROUP AVERAGE -1.9% Average four-week return.	TREND BREADTH 50.0% Share of peers with an active trend.
--	--	---

Peer	Exchange	1W return	4W return	Trend
BMJ	NYSE	2.2%	9.1%	Active
AMGN	NASDAQ	2.7%	4.9%	Active
GRFS	NASDAQ	4.3%	3.9%	Inactive
JNJ	NYSE	4.1%	3.4%	Active
ABBV	NYSE	1.9%	3.1%	Active

08 · EVIDENCE AND WEEKLY DATA

The underlying research record

Every top-level statement should be traceable to a stored market, fundamental, event, or positioning observation.

Cross-signal evidence matrix

Evidence pillar	Score / read	Summary	Detail
Weekly tape	74/100	Trend, activity pressure, participation, and risk combine to a 74/100 tape read.	
Indicator analysis	61/100	Latest 12-week confirmation: trend 12/12, activity pressure 4/12, relative leadership 11/12.	Activity pressure 0.64; 4 reversal markers
Factors	59/100	O'Shaughnessy factor stack blends value, quality, momentum, and confidence.	Buyback Yield rank 28
Patient Capital	Quiet	Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.	No recent buy signal
Options	55/100	JNJ shows bullish options pressure with a 48/100 conviction score, put-call volume ratio of 0.25, expected move of 2.2%, and Sharemaestro trend signal active.	Bullish · Call-side pressure · Expected move 2.2%
Sentiment	54/100	Weighted news tone is neutral across 38 relevant articles.	Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now
Insiders	13 / 7	13 acquisitions and 7 disposals in the latest 180-day insider tape.	
Earnings	76d	Next report is scheduled for 13 Oct 2026; event risk rises as the date approaches.	
Research flow	5 items	2 recent research articles and 3 Market Watch posts are available.	

Current evidence clusters

PRICE FOLLOW-THROUGH 4.1% Latest completed week; four-week move 3.4%.	INDICATOR STACK 100/95 Trend and activity pressure are weighted against the latest 12-week confirmation window.	TREND BACKDROP Active The trend backdrop defines the current weekly regime.	PATIENT CAPITAL Quiet Activity-pressure buy-signal status for institutional accumulation timing.
OPTIONS PRESSURE Bullish 48/100 conviction; expected move 2.2%.	NEWS SENTIMENT 54/100 38 relevant articles in the latest sentiment read.	EVENT RISK 76d Next report is scheduled for 13 Oct 2026; event risk rises as the date approaches.	

08 · EVIDENCE AND WEEKLY DATA · CONTINUED

Recent completed weeks

The completed weekly bars behind the report provide a compact audit trail for price, trend, Fair Value, activity pressure, leadership, and volume.

Week	Close	Return	Trend Line	Fair Value	Pressure	Leadership	Volume	Trend
24 Jul 2026	263.4 USD	4.1%	234.8 USD	169.9 USD	0.63	14.25	39.4M	On
17 Jul 2026	253.0 USD	-1.5%	232.8 USD	169.3 USD	0.63	9.76	45.9M	On
10 Jul 2026	257.0 USD	-2.3%	231.2 USD	168.6 USD	0.30	10.32	35.6M	On
03 Jul 2026	263.0 USD	3.3%	229.6 USD	167.9 USD	0.13	15.12	31.6M	On
26 Jun 2026	254.7 USD	11.5%	227.5 USD	167.2 USD	-0.20	14.64	54.9M	On
19 Jun 2026	228.4 USD	-5.2%	225.8 USD	166.5 USD	-0.69	1.04	43.0M	On
12 Jun 2026	240.9 USD	3.5%	224.9 USD	166.0 USD	-0.79	7.94	38.1M	On
05 Jun 2026	232.8 USD	3.3%	223.3 USD	165.4 USD	-0.96	5.34	35.5M	On
29 May 2026	225.3 USD	-3.3%	221.7 USD	164.9 USD	-1.06	-0.19	33.6M	On
22 May 2026	233.0 USD	3.4%	220.3 USD	164.4 USD	-1.05	4.96	37.1M	On
15 May 2026	225.4 USD	2.4%	218.8 USD	163.8 USD	-1.06	2.79	41.5M	On
08 May 2026	220.0 USD	-2.6%	217.6 USD	163.3 USD	-0.96	0.92	34.6M	On
01 May 2026	225.9 USD	-0.1%	216.5 USD	162.8 USD	-0.73	6.25	37.2M	On
24 Apr 2026	226.2 USD	-2.9%	215.2 USD	162.3 USD	-0.40	7.70	41.7M	On

How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown in the fundamentals section.

Educational market research only. Not financial, investment, trading, tax, or legal advice. Market data, indicators, summaries, and reports may be delayed, incomplete, or inaccurate. You are responsible for your own decisions and should seek independent professional advice where appropriate.

Open the live report · Open the interactive chart · Full disclaimer